Technology | May 31, 2011

UPPI Offers UltraSPECT’s Nuclear Imaging Technology for Dose Reduction, Abbreviated Scan Times

May 31, 2011 — UltraSPECT, a provider of nuclear medicine (NM) image reconstruction technology that reduces radiopharmaceutical dose and acquisition time, announces a multi-year distribution agreement with nuclear pharmacy network UPPI LLC for exclusive leasing and/or non-exclusive sale of UltraSPECT’s cardiac and bone imaging applications in the United States.

Ushering molecular imaging into a new age of precision and efficiency, UltraSPECT’s growing product line utilizes the company’s innovative wide-beam reconstruction (WBR) technology to enhance the performance of gamma cameras and PET scanners. The technology will cut either standard radiopharmaceutical dose requirements or imaging procedure time in half with no decrease in image quality, while enhancing image resolution. In some cases, exams can be performed in as little as a quarter of the standard procedure time. Additionally, advanced new UltraSPECT applications support a 50 percent reduction in both dose and procedure time.

UltraSPECT WBR’s lower dose requirements offer the benefit of minimizing radiation exposure for both patients and technologists, while abbreviated acquisition times reduce the possibility of patient motion artifacts and enhance patient throughput and comfort. Higher image resolution provides greater lesion localization, raising diagnostic confidence and precision. For many WBR users the result is enhanced equipment utilization, revenues and patient satisfaction and referrals.

UltraSPECT’s WBR product line is compatible with most major manufacturers’ NM and PET systems as well as all clinical software packages. The technology is a far more cost effective dose reduction alternative to today’s new low-dose SPECT cameras with multiple focused detectors. WBR’s half-dose, half-time and quarter-time capabilities are already successfully utilized in hundreds locations throughout the United States and Europe.

For more information: www.UPPI.org, www.ultraspect.com

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....